- ByProactive Investors
Nuformix plc is a United Kingdom-based pharmaceutical development company. The Company is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF) and possibly other fibrosing interstitial lung diseases (ILDs). NXP001, is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting (chemotherapy-induced nausea and vomiting). NXP004 is a form of Olaparib, which is used for the treatment of several cancers.